Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, and related immunomodulation programs. Company announcements highlight progress in neuroinflammatory and neurodegenerative indications, including non-active secondary progressive multiple sclerosis, early Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).
News about Tiziana often covers key clinical milestones. Recent releases describe dosing of patients in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early Alzheimer’s disease, including evaluation as monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab and donanemab. Other updates report on the Expanded Access Program in non-active secondary progressive multiple sclerosis and the acceptance of the company’s ALS Phase 2 trial into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS.
Investors following TLSA news can also expect regulatory and safety updates, such as the submission of Development Safety Update Reports to the U.S. Food and Drug Administration, which summarize cumulative exposure and safety findings for intranasal foralumab. Corporate and capital markets news includes insider share purchases by senior leadership, decisions regarding proposed public offerings, and participation in industry conferences like BIO-Europe, the Jefferies London Healthcare Conference, and neuroscience-focused forums.
This news page aggregates these company-issued press releases and related coverage, giving readers a centralized view of Tiziana’s clinical progress, regulatory interactions, strategic initiatives such as the planned spinout of IL-6 asset TZLS-501, and visibility events like ringing the Nasdaq Closing Bell. Users interested in TLSA can review this feed to monitor how Tiziana’s immunotherapy and drug delivery programs evolve over time.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that Panetta Partners Limited, linked to Executive Chairman Gabriele Cerrone, purchased 29,318 common shares at prices between $0.78 and $0.81, increasing Cerrone's stake from 37.70% to 37.72%. The company focuses on developing innovative drug delivery technologies for immunotherapies, with two lead candidates showing favorable safety and efficacy in clinical studies. Tiziana aims to enhance immunotherapy efficacy through alternative delivery methods such as nasal and oral routes.
Tiziana Life Sciences (Nasdaq: TLSA) has received a prestigious grant from the ALS Association for research on an intranasal anti-CD3 monoclonal antibody aimed at combating Amyotrophic Lateral Sclerosis (ALS) at Brigham and Women’s Hospital. The grant will facilitate studies on dampening microglial activation linked to ALS progression. Tiziana's foralumab, the first entirely human anti-CD3 monoclonal antibody, shows promise in treating various neuroinflammatory conditions including ALS and Alzheimer’s Disease. The company emphasizes the significant unmet need for effective ALS therapies.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced the purchase of 100,000 common shares by Chief Medical Officer Matthew Davis at $0.76 per share. This move reflects confidence in the company’s future amidst its development of innovative immunotherapies using alternative drug delivery methods. Tiziana's flagship products, intranasal foralumab and milciclib, have shown promising safety profiles and clinical responses. The company focuses on transforming immunotherapy delivery to enhance efficacy and safety compared to traditional intravenous methods.
Tiziana Life Sciences (Nasdaq: TLSA) announced that Panetta Partners Limited acquired 20,000 common shares at $0.75 each, increasing Executive Chairman Gabriele Cerrone's ownership from 37.60% to 37.61%. Tiziana is focused on developing innovative immunotherapies through novel drug delivery methods, including intranasal and oral routes, which show potential for better efficacy and safety compared to traditional IV methods. Their lead candidates, intranasal foralumab and milciclib, have shown favorable safety profiles and clinical responses in studies.
Tiziana Life Sciences (Nasdaq: TLSA) announced a study showing improved cognitive function and restored microglia homeostasis in animal models of Alzheimer’s disease. The research focused on intranasal anti-CD3 monoclonal antibody and was presented at the AAIC on July 31, 2022. With promising results, the company is considering clinical trials of Foralumab in Alzheimer’s patients. Dr. Howard Weiner emphasized its potential to modulate microglial activity and reduce inflammation, making it a novel approach for treating progressive neurological disorders.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced the appointment of Matthew Davis, MD, RPh as the Chief Medical Officer and Acting Chief Scientific Officer, effective immediately. Dr. Davis, with 25 years of pharmaceutical experience and notable FDA approvals under his belt, is expected to drive Tiziana's shift towards proof-of-concept clinical trials. His leadership is aimed at enhancing the development of therapies for Secondary-Progressive Multiple Sclerosis, Crohn's Disease, and KRAS+ NSCLC.
Tiziana Life Sciences (NASDAQ: TLSA) announced the resignation of Dr. Kunwar Shailubhai as CEO, CSO, and Board director effective August 1, 2022, due to personal reasons. The resignation is not related to any operational disagreements. Gabriele Cerrone, Executive Chairman, will serve as interim CEO while the Board searches for a permanent replacement. The company continues to advance its foralumab clinical programs and will provide progress updates in due course.
Tiziana Life Sciences (TLSA) announced on June 14, 2022, that it received a notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price for continued listing on the Nasdaq Global Market. The Company has 180 days to regain compliance by maintaining the closing bid price at or above $1.00 for at least ten consecutive business days. The notice does not affect the current trading of its securities. Tiziana aims to resolve this deficiency and may consider options to meet the bid price requirement before the compliance deadline of December 12, 2022.
Tiziana Life Sciences (Nasdaq: TLSA) announced on June 10, 2022, that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, purchased 50,000 common shares at $0.88 each. This acquisition increased Cerrone's stake from 37.60% to 37.64%. Tiziana specializes in developing innovative immunotherapy delivery methods, focusing on alternative routes such as nasal, oral, and inhalation. Their leading candidates include intranasal foralumab and milciclib, both of which have shown favorable safety profiles in clinical studies.
Tiziana Life Sciences PLC (NASDAQ: TLSA) announced positive clinical results for its second patient in a secondary progressive multiple sclerosis (SPMS) trial. The patient showed improvements in PET analysis and neurologic exams after three months of treatment with intranasal foralumab. Following these findings, the FDA approved the enrollment of eight additional patients in the trial. Tiziana aims to escalate dosing to potentially enhance clinical benefits. The company anticipates enrolling the third patient by July 2022 and expects to release data on all ten patients in 2023.